dihexa comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
The μ-opioid receptors (using the Greek letter mu, abbreviated MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. They are also referred to as μ(mu)-opioid peptide (MOP) receptors. The prototypical μ-opioid receptor agonist is morphine, the primary psychoactive alkaloid in opium and for which the receptor was named, with mu being the first letter of Morpheus, the compound's namesake in the original Greek. It is an inhibitory G-protein coupled receptor that activates the Gi alpha subunit, inhibiting adenylate cyclase activity, lowering cAMP levels.
== In fiction == The creation of a mirror-image human is the basis of the 1950 short story "Technical Error" by Arthur C. Clarke. In this story, a physical accident transforms a person into his mirror image, speculatively explained by travel through a fourth physical dimension. H. G. Wells' The Plattner Story (1896) is based on a similar idea. In the 1970 Star Trek novel Spock Must Die! by James Blish, the science officer of the USS Enterprise is replicated in mirror-image form by a transporter mishap. He locks himself in the sick bay where he is able to synthesize mirror-image forms of basic nutrients needed for his survival. An alien machine that reverses chirality, and a blood-symbiont that functions properly only when in one chirality, were central to Roger Zelazny's 1976 novel Doorways in the Sand. On the titular planet of Sheri S. Tepper's 1989 novel Grass, some lifeforms have evolved to use the right-handed isomer of alanine. In the Mass Effect series, chirality of amino acids in foodstuffs is discussed often in both dialogue and encyclopedia files. In the 2014 science fiction novel Cibola Burn by James S. A. Corey, the planet Ilus has indigenous life with partially-mirrored chirality. This renders human colonists unable to digest native flora and fauna, and greatly complicates conventional farming. Consequently, the colonists have to rely upon hydroponic farming and food importation. In the 2017 Daniel Suarez novel Change Agent, an antagonist, Otto, nicknamed the "Mirror Man", is revealed to be a genetically engineered mirror-image human.
has no real roots. While all of the above inequalities are true because a, b, and c must follow the basic triangle inequality that the longest side is less than half the perimeter, the following relations hold for all positive a, b, and c:
Single workplaces may have multiple unions, and in such cases an employer may apply to the FWC for an order that bargaining representatives meet to elect one to represent all of them if "the bargaining process is not proceeding efficiently or fairly because there are multiple bargaining representatives for the agreement."
Sources: en.wikipedia.org
cell physiology The study of the various biological activities and biochemical processes which sustain life inside cells, particularly (but not necessarily limited to) those related to metabolism and energy transfer, growth and reproduction, and the ordinary processes of the cell cycle.
Upon activation, bAREs ADP-ribosylate any number of eukaryotic proteins; such mechanism is crucial to the instigation of the diseased states associated with ADP-ribosylation. GTP-binding proteins, in particular, are well-established in bAREs pathophysiology. For examples, cholera and heat-labile enterotoxin target the α-subunit of Gs of heterotrimeric GTP-binding proteins. As the α-subunit is ADP-ribosylated, it is permanently in an "active", GTP-bound state; subsequent activation of intracellular cyclic AMP stimulates the release of fluid and ions from intestinal epithelial cells. Furthermore, C. Botulinum C3 ADP-ribosylates GTP-binding proteins Rho and Ras, and Pertussis toxin ADP-ribosylates Gi, Go, and Gt. Diphtheria toxin ADP-ribosylates ribosomal elongation factor EF-2, which attenuates protein synthesis. There are a variety of bacteria which employ bAREs in infection: CARDS toxin of Mycoplasma pneumoniae, cholera toxin of Vibrio cholerae; heat-labile enterotoxin of E. coli; exotoxin A of Pseudomonas aeruginosa; pertussis toxin of B. pertussis; C3 toxin of C. botulinum; and diphtheria toxin of Corynebacterium diphtheriae.
Capillary penetration in porous media shares its dynamic mechanism with flow in hollow tubes, as both processes are resisted by viscous forces. Consequently, a common apparatus used to demonstrate the phenomenon is the capillary tube. When the lower end of a glass tube is placed in a liquid, such as water, a concave meniscus forms. Adhesion occurs between the fluid and the solid inner wall pulling the liquid column along until there is a sufficient mass of liquid for gravitational forces to overcome these intermolecular forces. The contact length (around the edge) between the top of the liquid column and the tube is proportional to the radius of the tube, while the weight of the liquid column is proportional to the square of the tube's radius. So, a narrow tube will draw a liquid column along further than a wider tube will, given that the inner water molecules cohere sufficiently to the outer ones.
Several forms (vitamers) of vitamin D exist, with the two major forms being vitamin D2 (ergocalciferol), and vitamin D3 (cholecalciferol). The common-use term "vitamin D" refers to both D2 and D3, which were chemically characterized, respectively, in 1931 and 1935. Vitamin D3 was shown to result from the ultraviolet irradiation of 7-dehydrocholesterol. Although a chemical nomenclature for vitamin D forms was recommended in 1981, alternative names remain commonly used. Chemically, the various forms of vitamin D are secosteroids, meaning that one of the bonds in the steroid rings is broken. The structural difference between vitamin D2 and vitamin D3 lies in the side chain: vitamin D2 has a double bond between carbons 22 and 23, and a methyl group on carbon 24. Vitamin D analogues have also been synthesized. US dietary guides generally assume that all of a person's vitamin D is taken orally, given the potential for insufficient sunlight exposure due to urban living, cultural choices for the amount of clothing worn when outdoors, and use of sunscreen because of concerns about safe levels of sunlight exposure, including the risk of skin cancer.
In addition to numerous cooperative law enforcement actions worldwide against drug trafficking and money laundering, the DEA and other agencies, and the US military, have been involved in multi-year foreign drug campaigns, including in Colombia, Mexico and Afghanistan. On January 3, 2026, the United States launched a large-scale military operation, including airstrikes across northern Venezuela, and captured Venezuelan President Nicolas Maduro and his wife, Cilia Flores, during a raid in Caracas. U.S. forces flew them to New York, where they are to face federal charges including narco-terrorism and cocaine trafficking related to a long-standing indictment.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.